Salla Kuusela

Salla Kuusela

Auto-generated profile, based on publicly available information

Salla Kuusela

Department of Pediatrics, Research Unit of Clinical Medicine, Medical Research Center, University of Oulu, Oulu, Finland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2020 in Pediatric Diabetes
Verified
Journal Article
Open access
PDF file
SKSalla Kuusela
Salla Kuusela
PKPäivi Keskinen
Päivi Keskinen
TPTytti Pokka
Tytti Pokka
MKMikael Knip
Mikael Knip
JIJorma Ilonen
Jorma Ilonen
RVRiitta Veijola
Riitta Veijola
Objective The aim of this study was to explore the extended family history of type 1 diabetes in children at genetic risk and define the impact of a positive family history on the development of islet autoimmunity and type 1 diabetes. Methods The subjects were participants in The Finnish Type 1 Diabetes Prediction and Prevention (DIPP) study and carried increased HLA‐conferred risk for type 1 diabetes. The case children (n=343) were positive for at least one islet autoantibody, and the control children (n=343) matched by age, gender and class II HLA genotype were negative for islet autoantibodies at the time of data collection. Extended family history of type 1 diabetes was obtained by using a structured questionnaire. Results Among children who were autoantibody positive and progressed to type 1 diabetes 62.2% (28/45) had at least one relative with type 1 diabetes. Interestingly, 57.8% of these children (26/45) had such a relative outside the nuclear family compared to 30.7% of children with no autoantibodies (P=0.001), 35.2% of those with only classical islet cell antibodies (P=0.006), and 35.2% of non‐progressors with biochemical autoantibodies (P=0.011). A positive history of type 1 diabetes in the paternal extended family was more common in children with multiple biochemical autoantibodies compared to those with only one biochemical autoantibody (P=0.010). No association between the specificity of the first appearing autoantibody and family history of the disease was found. Conclusions Type 1 diabetes in relatives outside the nuclear family is a significant risk factor for islet autoimmunity and progression to clinical disease in HLA susceptible children.

8 November 2025 in Diabetologia
Verified
Journal Article
Open access
PDF file
SKSalla Kuusela
Salla Kuusela
JKJaakko J. Koskenniemi
Jaakko J. Koskenniemi
TVToni Valtanen
Toni Valtanen
TPTytti Pokka
Tytti Pokka
THTaina Härkönen
Taina Härkönen
RVRiitta Veijola
Riitta Veijola
Aims/hypothesis: Islet autoimmunity during presymptomatic type 1 diabetes is heterogeneous. We hypothesised that a positive family history of type 1 diabetes is associated with specific characteristics of the autoimmune process resulting in clinical diabetes. In a prospective birth cohort study, we compared the initiation and evolution of islet autoimmunity and the rate of progression from islet autoimmunity to diabetes between children with and without a first-degree relative (FDR) with type 1 diabetes. Methods: In the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) study, we prospectively followed children with HLA-conferred susceptibility from birth for the appearance of islet autoantibodies (IAA, GADA, IA-2A, ZnT8A), further development of islet autoimmunity, and progression to clinical diabetes. The presence of type 1 diabetes among their FDRs was recorded at the time of birth, and the family history data was updated during the follow-up period. Results: Among a total of 1334 children with confirmed positivity for at least one islet autoantibody, 145 (10.9%) had one or more FDRs with type 1 diabetes at the time of birth (FDR+). During a median follow-up period of 8.6 years, FDRs of an additional 87 children developed type 1 diabetes (FDR− FDR+). At seroconversion, both FDR+ and FDR− FDR+ children were significantly more often positive for GADA and multiple autoantibodies than children without affected FDRs (FDR−). The seroconversion age was similar between the three groups (median 2.7 vs 2.1 vs 3.0 years in FDR+, FDR− FDR+ and FDR− children, respectively). During the follow-up period, FDR+ and FDR− FDR+ children more often had IAA, GADA, IA-2A and multiple autoantibodies than FDR− children, and progressed more frequently to diabetes (55.9 vs 57.5 vs 38.9%, respectively). Time from seroconversion to clinical diabetes was significantly shorter in FDR+ children compared with FDR− children (2.7 vs 3.6 years). Children with paternal type 1 diabetes at birth ( n =71; i.e., the father had type 1 diabetes) were twice as often positive for multiple autoantibodies at seroconversion as those with maternal type 1 diabetes ( n =50; i.e. the mother had type 1 diabetes) (39.4% vs 20.0%). Conclusions/interpretation: At seroconversion, genetically susceptible children who had one or more FDRs with type 1 diabetes, especially an affected father, were more often positive for GADA and multiple islet autoantibodies. During the follow-up period, children with an affected FDR were more often positive for IAA, GADA and IA-2A, and progressed to clinical type 1 diabetes more often and faster than children without an affected FDR. These data should be considered when designing intervention and screening studies. Graphical